Abridge doubled its valuation to $5.3B in June 2025 four months after its $250M Series D, closing a $300M Series E led by a16z and Khosla, reaching $117M in contracted ARR with deployments across 150+ health systems. That trajectory — plus OpenEvidence's $735M Series D at $12B and Hippocratic AI's $335M Series B at $1.64B — is why AI Healthcare shifted from regulatory-bound experiment into a vertical with pricing power inside Epic and Cerner contracts.
Scribes ate the pilot budgets
Ambient documentation is the breakout subcategory. Abridge's Epic Systems integration moved scribing from pilot line item to recurring infrastructure. Ambience Healthcare ($243M Series C, $1B valuation) targets multi-specialty rollouts; Suki AI ($70M Series C, $400M valuation) leans on a voice-assistant interface; Nabla ships in France and the US; Heidi AI and Lyrebird Health push into Australia. Epic's own AI scribe, announced in 2024, is the platform risk every standalone vendor models against.
OpenEvidence ($735M Series D, $12B valuation) leads clinical decision support. The pitch is retrieval-grounded medical reasoning clinicians can audit — citations to actual literature, not stochastic LLM output. The valuation prices in the bet that physician adoption translates to enterprise deals once payer and EHR integrations land.
Hippocratic and the voice layer
Hippocratic AI's $335M Series B funds a constitutional approach: refuse-by-default on diagnosis or prescribing, agents restricted to non-clinical tasks like appointment prep, post-discharge follow-up, and medication reminders. The architecture lets health systems deploy voice without expanding malpractice exposure.
Drug discovery is the split-personality subcategory. Recursion has clinical-stage assets and pharma partnerships; Chai Discovery ($130M Series B) is upstream on antibody design; Color Health rebuilds cancer care delivery; Insilico Medicine, Atomwise, EvolutionaryScale, and Xaira each bet on different AI-as-tool versus AI-native pipelines.
Regulation, not capability, is the bottleneck
FDA pathway clarity for adaptive AI medical devices and CMS reimbursement codes for ambient documentation set the 2026 spending curve more than any model improvement. Lunit (radiology, Korea), Tempus (precision medicine), Owkin (R&D), Notable (operations), and Glass Health (decision support) are positioning for whichever regulatory door opens first.